CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向表观遗传调控因子增强抗肿瘤 T 细胞免疫治疗
英文原题：Targeting epigenetic regulators to boost T cell immunotherapy against cancer.
查看英文原题
Targeting epigenetic regulators to boost T cell immunotherapy against cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
表观遗传调控对T细胞分化、功能和命运至关重要，因此会影响T细胞免疫疗法的成效。本综述首先回顾癌症T细胞免疫治疗的发展，然后考察DNA甲基化、mRNA甲基化和组蛋白甲基化等关键表观遗传调控因素，以及它们在感染和肿瘤发生过程中塑造T细胞状态的作用。文章结合免疫治疗疗效讨论这些调控因素对T细胞耗竭和谱系定向的影响，重点介绍靶向表观遗传通路以增强CAR-T 和TCR疗法的近期进展，最后总结提高过继T细胞疗法持久性和有效性的现有挑战及新兴策略。
展开英文摘要原文
Epigenetic regulation is crucial in directing T-cell differentiation, function, and fate, thereby influencing the success of T-cell-based immunotherapies. This review begins with an overview of the evolution of T-cell immunotherapies in cancer treatment.
We then examine key epigenetic regulators-such as DNA methylation, mRNA methylation, and histone methylation-and their roles in shaping T-cell states during infection and tumorigenesis. The contributions of these regulators to T-cell exhaustion and lineage commitment are discussed in the context of immunotherapy efficacy.
We highlight recent advances in targeting epigenetic pathways to enhance CAR-T and TCR-based therapies and conclude with current challenges and emerging strategies to improve the durability and effectiveness of adoptive T-cell therapies.
论文信息
- 作者
- Xiao T、Zhang YE
- 单位
- Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Building 37, RM 2056, Bethesda, MD, 20892-4256, USA. tiaojiang.xiao@nih.gov.United States
- 文献类型
- 综述
- 期刊
- Cell & bioscience2026 Feb 3
- 原文标识
- PubMed 41634788 · DOI 10.1186/s13578-026-01533-y
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →